Sartorius sees 21% YoY increase in net profit for 1Q25 on 7% sales growth. The company expects 6% sales growth in 2025 with EBITDA margin improvement. Result is positive for biopharma CDMO players.
What is covered in the Full Insight:
Overview of Sartorius AG's 1Q25 Performance
Bioprocessing Solutions Division as a Growth Engine
2025 Financial Guidance by Sartorius
Implications for Downstream Bioprocessing Companies